125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma

Figure 1 Characterization of anti-bFGF mAb. A: SDS-PAGE of purified bFGF mAb (H: heavy chain; L: light chain); B: Titer of purified bFGF mAb stock solution tested by indirect ELISA; C: Concentration of purified bFGF mAb stock solution assayed by BCA standard assay kit. (Standard curve: y = 0.0011x + 0.2645; Relevancy: R² = 0.9911). BCA: Bicinchoninic acid; bFGF: Basic fibroblast growth factor; ELISA: Enzyme-linked immunosorbent assay; mAB: Monoclonal antibody; SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Figure 2 Radioactivity and titer of purified ¹²⁵I-bFGF mAb. A: Product peak of purified ¹²⁵I-bFGF mAb tested by gamma radiation counter GC-1200; B: Titer of purified ¹²⁵I-bFGF mAb stock solution assayed by indirect ELISA.

Figure 3 Therapeutic efficacy of ¹²⁵I-bFGF mAb in mice with H22 hepatocellular carcinoma. A: Tumor volume of H22 HCC; B: Tumor weight of H22 HCC; C: Tumor inhibition ratios of experimental groups; ^aP < 0.05, ¹²⁵I-bFGF mAb group vs other groups (control, ¹²⁵I, bFGF mAb and ¹²⁵I plus bFGF mAb). HCC: Hepatocellular carcinoma.

Figure 4 Quantitative real-time reverse transcriptase polymerase chain reaction amplification curves, melt curves and expression of bFGF, FGFR, VEGF and PDGF mRNA. ^aP < 0.05, ¹²⁵I-bFGF mAb group vs other groups (control, ¹²⁵I, bFGF mAb and ¹²⁵I plus bFGF mAb). qRT-PCR: Quantitative real-time reverse transcriptase polymerase chain reaction.